MedPath

Cardiopulmonary Stress Testing (CPET) AlloSure Study

Recruiting
Conditions
Transplant; Failure, Heart
Heart Failure
Interventions
Behavioral: CPET exercise testing
Registration Number
NCT04656080
Lead Sponsor
Baylor Research Institute
Brief Summary

1. Cell-free DNA does not vary significantly as a function of the activity of immunologically quiescent cardiac transplant recipients, despite the metabolic demands of the transplanted organ. (The implication of the null result would be that no restrictions to patient activity, nor modification of cardiac rehabilitation prescription, would be necessary to maintain proper test characteristics of AlloSure testing).

2. In immunologically active cardiac transplant allografts, exercise prior to assay of donor-derived cell-free DNA can be used to increase the sensitivity of the AlloSure test. (The implication of this would be that the optimal time-frame for drawing an Allosure may actually be post-exercise, and that window will be characterized).

Detailed Description

The specific research questioned aimed to be addressed with this proposed study are:

i. Are dd-cfDNA levels in heart transplant recipients independent of recent cardiopulmonary exercise? More specifically, does the metabolic demand of maximal cardiopulmonary exercise in recent heart transplant recipients trigger a release of dd-cfDNA (if so, then what is the time course for resolution back to baseline?) ii. If dd-cfDNA does not release to any significant degree with cardiac allografts with short donor-ischemic time, does this test characteristic continue to hold for cardiac allografts transplanted after longer donor ischemic times? iii. In cardiac transplant recipients with medically stabilized, treated antibody-mediated rejection (AMR) and persistent dd-cfDNA elevation, does a discrete episode of maximal cardiometabolic activity trigger any additional elevation of dd-cfDNA, and again, with what time course?

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
27
Inclusion Criteria

Post-orthotopic heart transplant patients

Exclusion Criteria
  1. orthopedic, neurologic and/or any other limitations that do not allow for exercise testing on a treadmill or cycle ergometer;
  2. individuals who require supplemental oxygen or have current permanent tracheostomies will be excluded from this study;
  3. individuals who are discharged to a long-term acute care facility;
  4. skilled nursing facility or with palliative care or hospice care will be excluded; (e) inmates and pregnant women;

(f) patients with antibody-mediate rejection that are not felt to be safe for cardiopulmonary stress testing.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
3 months post-heart transplant with AMRCPET exercise testing• 7 transplant recipients, at least 3 months post-transplant, with antibody-mediated rejection
transplant recipients <1year without AMRCPET exercise testing20 recent transplant recipients (\<1 year) without antibody-mediated rejection (AMR);
Primary Outcome Measures
NameTimeMethod
• Comparison of level of cell-free DNA10 days

Comparison of level of cell-free DNA

• Comparison of maximal oxygen consumption (VO2)10 days

• Comparison of maximal oxygen consumption (VO2)

• Cell-free DNA (AlloSure) levels after maximal cardiopulmonary exercise10 days

• Cell-free DNA (AlloSure) levels after maximal cardiopulmonary exercise

Secondary Outcome Measures
NameTimeMethod
• Time-dependent changes in high-sensitivity troponin-levels10 days

• Time-dependent changes in high-sensitivity troponin-levels

Trial Locations

Locations (1)

Baylor Scott & White health research institute

🇺🇸

Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath